ML17349A173: Difference between revisions
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
||
| Line 16: | Line 16: | ||
=Text= | =Text= | ||
{{#Wiki_filter:tinitnt ~rates ~cnatc The Honorable Kristine L. Svinicki Chairman U.S. Nuclear Regulatory Commission Washington, DC 20555-0001 Dear Chairman | {{#Wiki_filter:tinitnt ~rates ~cnatc The Honorable Kristine L. Svinicki Chairman U.S. Nuclear Regulatory Commission Washington, DC 20555-0001 | ||
==Dear Chairman Svinicki,== | |||
WASHINGTON, DC 20510 December 14, 2017 We are writing in support of the Northwest Medical Isotopes (NWMI) application to construct a medical radioisotope production facility in Missouri. | |||
The Commission has scheduled a hearing in January regarding the application from NWMJ for a construction permit. The U.S. currently cannot produce molybdenum-99 (Mo-99) domestically. | The Commission has scheduled a hearing in January regarding the application from NWMJ for a construction permit. The U.S. currently cannot produce molybdenum-99 (Mo-99) domestically. | ||
This short-lived isotope decays into technetiurn-99 (Tc-99) which, in turn, is used in medical imaging for many diseases, including cancer and heart disease. | This short-lived isotope decays into technetiurn-99 (Tc-99) which, in turn, is used in medical imaging for many diseases, including cancer and heart disease. The lack of U.S. production capacity is a problem that has plagued the U.S. radiopharmaceutical industry for decades. It is our understanding that this one facility would have the ability to supply nearly half of the U.S. demand for these isotopes. | ||
The lack of U.S. production capacity is a problem that has plagued the U.S. radiopharmaceutical industry for decades. | |||
It is our understanding that this one facility would have the ability to supply nearly half of the U.S. demand for these isotopes. | |||
NWMl, an innovative Oregon company, in partnership with Oregon State University and the University of Missouri, is seeking to address this U.S. reliance on uncertain foreign sources of these radioisotopes by building a production facility in Columbia, Missouri. | NWMl, an innovative Oregon company, in partnership with Oregon State University and the University of Missouri, is seeking to address this U.S. reliance on uncertain foreign sources of these radioisotopes by building a production facility in Columbia, Missouri. | ||
Columbia is home to the University of Missouri's renowned research reactor (MURR). The design of the irradiation targets is based on the work of researchers at Oregon State University which lead to the creation of NWMI. The issuance of a construction permit for this facility would be a significant milestone in obtaining a domestic supply for this important national radiopharmaceutical technology. | Columbia is home to the University of Missouri's renowned research reactor (MURR). The design of the irradiation targets is based on the work of researchers at Oregon State University which lead to the creation of NWMI. The issuance of a construction permit for this facility would be a significant milestone in obtaining a domestic supply for this important national radiopharmaceutical technology. | ||
We ask the Commission to give NWMI's application its full and fair consideration. (;u~ Ron Wyden United States Senator Cc: Hon. Jeff Baran, Commissioner Hon. Stephen G. Burns, Commissioner Sincerely, Claire McCaskill United States Senator}} | We ask the Commission to give NWMI's application its full and fair consideration. (;u~ Ron Wyden United States Senator Cc: Hon. Jeff Baran, Commissioner Hon. Stephen G. Burns, Commissioner Sincerely, Claire McCaskill United States Senator}} | ||
Revision as of 05:49, 6 July 2018
| ML17349A173 | |
| Person / Time | |
|---|---|
| Site: | Northwest Medical Isotopes |
| Issue date: | 12/14/2017 |
| From: | McCaskill C, Wyden R US SEN (Senate) |
| To: | Svinicki K L NRC/Chairman |
| SECY/RAS | |
| References | |
| 50-609-CP, Construction Permit Mandatory Hrg | |
| Download: ML17349A173 (1) | |
Text
tinitnt ~rates ~cnatc The Honorable Kristine L. Svinicki Chairman U.S. Nuclear Regulatory Commission Washington, DC 20555-0001
Dear Chairman Svinicki,
WASHINGTON, DC 20510 December 14, 2017 We are writing in support of the Northwest Medical Isotopes (NWMI) application to construct a medical radioisotope production facility in Missouri.
The Commission has scheduled a hearing in January regarding the application from NWMJ for a construction permit. The U.S. currently cannot produce molybdenum-99 (Mo-99) domestically.
This short-lived isotope decays into technetiurn-99 (Tc-99) which, in turn, is used in medical imaging for many diseases, including cancer and heart disease. The lack of U.S. production capacity is a problem that has plagued the U.S. radiopharmaceutical industry for decades. It is our understanding that this one facility would have the ability to supply nearly half of the U.S. demand for these isotopes.
NWMl, an innovative Oregon company, in partnership with Oregon State University and the University of Missouri, is seeking to address this U.S. reliance on uncertain foreign sources of these radioisotopes by building a production facility in Columbia, Missouri.
Columbia is home to the University of Missouri's renowned research reactor (MURR). The design of the irradiation targets is based on the work of researchers at Oregon State University which lead to the creation of NWMI. The issuance of a construction permit for this facility would be a significant milestone in obtaining a domestic supply for this important national radiopharmaceutical technology.
We ask the Commission to give NWMI's application its full and fair consideration. (;u~ Ron Wyden United States Senator Cc: Hon. Jeff Baran, Commissioner Hon. Stephen G. Burns, Commissioner Sincerely, Claire McCaskill United States Senator